151 related articles for article (PubMed ID: 18038218)
1. Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck.
Tang PA; Siu LL; Chen EX; Hotte SJ; Chia S; Schwarz JK; Pond GR; Johnson C; Colevas AD; Synold TW; Vasist LS; Winquist E
Invest New Drugs; 2008 Jun; 26(3):257-64. PubMed ID: 18038218
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial.
Lee CW; Bélanger K; Rao SC; Petrella TM; Tozer RG; Wood L; Savage KJ; Eisenhauer EA; Synold TW; Wainman N; Seymour L
Invest New Drugs; 2008 Jun; 26(3):249-55. PubMed ID: 17962907
[TBL] [Abstract][Full Text] [Related]
3. A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168).
Knox JJ; Gill S; Synold TW; Biagi JJ; Major P; Feld R; Cripps C; Wainman N; Eisenhauer E; Seymour L
Invest New Drugs; 2008 Jun; 26(3):265-72. PubMed ID: 18196204
[TBL] [Abstract][Full Text] [Related]
4. Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanes.
Beer TM; Goldman B; Synold TW; Ryan CW; Vasist LS; Van Veldhuizen PJ; Dakhil SR; Lara PN; Drelichman A; Hussain MH; Crawford ED
Clin Genitourin Cancer; 2008 Sep; 6(2):103-9. PubMed ID: 18824433
[TBL] [Abstract][Full Text] [Related]
5. Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancer.
Gomez HL; Philco M; Pimentel P; Kiyan M; Monsalvo ML; Conlan MG; Saikali KG; Chen MM; Seroogy JJ; Wolff AA; Escandon RD
Anticancer Drugs; 2012 Mar; 23(3):335-41. PubMed ID: 22123335
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors.
Burris HA; Jones SF; Williams DD; Kathman SJ; Hodge JP; Pandite L; Ho PT; Boerner SA; Lorusso P
Invest New Drugs; 2011 Jun; 29(3):467-72. PubMed ID: 20069338
[TBL] [Abstract][Full Text] [Related]
7. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.
Machiels JP; Haddad RI; Fayette J; Licitra LF; Tahara M; Vermorken JB; Clement PM; Gauler T; Cupissol D; Grau JJ; Guigay J; Caponigro F; de Castro G; de Souza Viana L; Keilholz U; Del Campo JM; Cong XJ; Ehrnrooth E; Cohen EE;
Lancet Oncol; 2015 May; 16(5):583-94. PubMed ID: 25892145
[TBL] [Abstract][Full Text] [Related]
8. Activity of the kinesin spindle protein inhibitor ispinesib (SB-715992) in models of breast cancer.
Purcell JW; Davis J; Reddy M; Martin S; Samayoa K; Vo H; Thomsen K; Bean P; Kuo WL; Ziyad S; Billig J; Feiler HS; Gray JW; Wood KW; Cases S
Clin Cancer Res; 2010 Jan; 16(2):566-76. PubMed ID: 20068098
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck.
Okuno SH; Mailliard JA; Suman VJ; Edmonson JH; Creagan ET; Nair S; Levitt R; Kugler JW
Cancer; 2002 Apr; 94(8):2224-31. PubMed ID: 12001121
[TBL] [Abstract][Full Text] [Related]
10. A pediatric phase I trial and pharmacokinetic study of ispinesib: a Children's Oncology Group phase I consortium study.
Souid AK; Dubowy RL; Ingle AM; Conlan MG; Sun J; Blaney SM; Adamson PC
Pediatr Blood Cancer; 2010 Dec; 55(7):1323-8. PubMed ID: 20712019
[TBL] [Abstract][Full Text] [Related]
11. A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours.
Blagden SP; Molife LR; Seebaran A; Payne M; Reid AH; Protheroe AS; Vasist LS; Williams DD; Bowen C; Kathman SJ; Hodge JP; Dar MM; de Bono JS; Middleton MR
Br J Cancer; 2008 Mar; 98(5):894-9. PubMed ID: 18319713
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma.
Adamo V; Ferraro G; Pergolizzi S; Sergi C; Laudani A; Settineri N; Alafaci E; Scimone A; Spano F; Spitaleri G
Oral Oncol; 2004 May; 40(5):525-31. PubMed ID: 15006626
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group.
Schöffski P; Catimel G; Planting AS; Droz JP; Verweij J; Schrijvers D; Gras L; Schrijvers A; Wanders J; Hanauske AR
Ann Oncol; 1999 Jan; 10(1):119-22. PubMed ID: 10076732
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.
Cohen EE; Rosen F; Stadler WM; Recant W; Stenson K; Huo D; Vokes EE
J Clin Oncol; 2003 May; 21(10):1980-7. PubMed ID: 12743152
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of TAS-106 in patients with platinum-failure recurrent or metastatic head and neck cancer and nasopharyngeal cancer.
Tsao A; Hui EP; Juergens R; Marur S; Huat TE; Cher GB; Hong RL; Hong WK; Chan AT
Cancer Med; 2013 Jun; 2(3):351-9. PubMed ID: 23930212
[TBL] [Abstract][Full Text] [Related]
16. Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program.
Carol H; Lock R; Houghton PJ; Morton CL; Kolb EA; Gorlick R; Reynolds CP; Maris JM; Keir ST; Billups CA; Smith MA
Pediatr Blood Cancer; 2009 Dec; 53(7):1255-63. PubMed ID: 19554570
[TBL] [Abstract][Full Text] [Related]
17. Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.
Soulières D; Faivre S; Mesía R; Remenár É; Li SH; Karpenko A; Dechaphunkul A; Ochsenreither S; Kiss LA; Lin JC; Nagarkar R; Tamás L; Kim SB; Erfán J; Alyasova A; Kasper S; Barone C; Turri S; Chakravartty A; Chol M; Aimone P; Hirawat S; Licitra L
Lancet Oncol; 2017 Mar; 18(3):323-335. PubMed ID: 28131786
[TBL] [Abstract][Full Text] [Related]
18. Randomized Phase II Study of Cabazitaxel Versus Methotrexate in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-Based Therapy.
Machiels JP; Van Maanen A; Vandenbulcke JM; Filleul B; Seront E; Henry S; D'Hondt L; Lonchay C; Holbrechts S; Boegner P; Brohee D; Dequanter D; Louviaux I; Sautois B; Whenham N; Berchem G; Vanderschueren B; Fontaine C; Schmitz S; Gillain A; Schoonjans J; Rottey S
Oncologist; 2016 Dec; 21(12):1416-e17. PubMed ID: 27903924
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck.
Specht L; Larsen SK; Hansen HS
Ann Oncol; 2000 Jul; 11(7):845-9. PubMed ID: 10997812
[TBL] [Abstract][Full Text] [Related]
20. Lack of efficacy of topotecan in the treatment of metastatic or recurrent squamous carcinoma of the head and neck: an Eastern Cooperative Oncology Group Trial (E3393).
Murphy BA; Leong T; Burkey B; Langer C; Forastiere A
Am J Clin Oncol; 2001 Feb; 24(1):64-6. PubMed ID: 11232952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
